Intensity of metastasis screening and survival outcomes in patients with breast cancer

Abstract Previous randomized trials, performed decades ago, showed no survival benefit of intensive screening for distant metastasis in breast cancer. However, recent improvements in targeted therapies and diagnostic accuracy of imaging have again raised the question of the clinical benefit of scree...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jong-Ho Cheun, Jigwang Jung, Eun-Shin Lee, Jiyoung Rhu, Han-Byoel Lee, Kyung-Hun Lee, Tae-Yong Kim, Wonshink Han, Seock-Ah Im, Dong-Young Noh, Hyeong-Gon Moon
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/2a3820548ebf4179b040a2bb00b178fe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2a3820548ebf4179b040a2bb00b178fe
record_format	dspace
spelling	oai:doaj.org-article:2a3820548ebf4179b040a2bb00b178fe2021-12-02T10:44:08ZIntensity of metastasis screening and survival outcomes in patients with breast cancer10.1038/s41598-021-82485-w2045-2322https://doaj.org/article/2a3820548ebf4179b040a2bb00b178fe2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82485-whttps://doaj.org/toc/2045-2322Abstract Previous randomized trials, performed decades ago, showed no survival benefit of intensive screening for distant metastasis in breast cancer. However, recent improvements in targeted therapies and diagnostic accuracy of imaging have again raised the question of the clinical benefit of screening for distant metastasis. Therefore, we investigated the association between the use of modern imaging and survival of patients with breast cancer who eventually developed distant metastasis. We retrospectively reviewed data of 398 patients who developed distant metastasis after their initial curative treatment between January 2000 and December 2015. Patients in the less-intensive surveillance group (LSG) had significantly longer relapse-free survival than did patients in the intensive surveillance group (ISG) (8.7 vs. 22.8 months; p = 0.002). While the ISG showed worse overall survival than the LSG did (50.2 vs. 59.9 months; p = 0.015), the difference was insignificant after adjusting for other prognostic factors. Among the 225 asymptomatic patients whose metastases were detected on imaging, the intensity of screening did not affect overall survival. A small subgroup of patients showed poor survival outcomes when they underwent intensive screening. Patients with HR-/HER2 + tumors and patients who developed lung metastasis in the LSG had better overall survival than those in the ISG did. Highly intensive screening for distant metastasis in disease-free patients with breast cancer was not associated with significant survival benefits, despite the recent improvements in therapeutic options and diagnostic techniques.Jong-Ho CheunJigwang JungEun-Shin LeeJiyoung RhuHan-Byoel LeeKyung-Hun LeeTae-Yong KimWonshink HanSeock-Ah ImDong-Young NohHyeong-Gon MoonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jong-Ho Cheun Jigwang Jung Eun-Shin Lee Jiyoung Rhu Han-Byoel Lee Kyung-Hun Lee Tae-Yong Kim Wonshink Han Seock-Ah Im Dong-Young Noh Hyeong-Gon Moon Intensity of metastasis screening and survival outcomes in patients with breast cancer
description	Abstract Previous randomized trials, performed decades ago, showed no survival benefit of intensive screening for distant metastasis in breast cancer. However, recent improvements in targeted therapies and diagnostic accuracy of imaging have again raised the question of the clinical benefit of screening for distant metastasis. Therefore, we investigated the association between the use of modern imaging and survival of patients with breast cancer who eventually developed distant metastasis. We retrospectively reviewed data of 398 patients who developed distant metastasis after their initial curative treatment between January 2000 and December 2015. Patients in the less-intensive surveillance group (LSG) had significantly longer relapse-free survival than did patients in the intensive surveillance group (ISG) (8.7 vs. 22.8 months; p = 0.002). While the ISG showed worse overall survival than the LSG did (50.2 vs. 59.9 months; p = 0.015), the difference was insignificant after adjusting for other prognostic factors. Among the 225 asymptomatic patients whose metastases were detected on imaging, the intensity of screening did not affect overall survival. A small subgroup of patients showed poor survival outcomes when they underwent intensive screening. Patients with HR-/HER2 + tumors and patients who developed lung metastasis in the LSG had better overall survival than those in the ISG did. Highly intensive screening for distant metastasis in disease-free patients with breast cancer was not associated with significant survival benefits, despite the recent improvements in therapeutic options and diagnostic techniques.
format	article
author	Jong-Ho Cheun Jigwang Jung Eun-Shin Lee Jiyoung Rhu Han-Byoel Lee Kyung-Hun Lee Tae-Yong Kim Wonshink Han Seock-Ah Im Dong-Young Noh Hyeong-Gon Moon
author_facet	Jong-Ho Cheun Jigwang Jung Eun-Shin Lee Jiyoung Rhu Han-Byoel Lee Kyung-Hun Lee Tae-Yong Kim Wonshink Han Seock-Ah Im Dong-Young Noh Hyeong-Gon Moon
author_sort	Jong-Ho Cheun
title	Intensity of metastasis screening and survival outcomes in patients with breast cancer
title_short	Intensity of metastasis screening and survival outcomes in patients with breast cancer
title_full	Intensity of metastasis screening and survival outcomes in patients with breast cancer
title_fullStr	Intensity of metastasis screening and survival outcomes in patients with breast cancer
title_full_unstemmed	Intensity of metastasis screening and survival outcomes in patients with breast cancer
title_sort	intensity of metastasis screening and survival outcomes in patients with breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/2a3820548ebf4179b040a2bb00b178fe
work_keys_str_mv	AT jonghocheun intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT jigwangjung intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT eunshinlee intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT jiyoungrhu intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT hanbyoellee intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT kyunghunlee intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT taeyongkim intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT wonshinkhan intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT seockahim intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT dongyoungnoh intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer AT hyeonggonmoon intensityofmetastasisscreeningandsurvivaloutcomesinpatientswithbreastcancer
_version_	1718396816202924032

Intensity of metastasis screening and survival outcomes in patients with breast cancer

Ejemplares similares